KIT and melanoma: Altogether, our results supported the notion that the transcriptional activation of oncogenes in BRAF-mutant melanoma cells could be suppressed through the stabilization of G4s within gene promoters, and indicated that G4-stabilizing compounds could be used to interfere with oncogene expression, especially KIT and BCL-2, in a “double-hit” manner.